PainReform Ltd. (PRFX)
NASDAQ: PRFX · Real-Time Price · USD
3.100
-0.050 (-1.59%)
At close: Mar 3, 2025, 4:00 PM
3.011
-0.089 (-2.86%)
Pre-market: Mar 4, 2025, 8:03 AM EST
Company Description
PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel.
It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations.
The company was incorporated in 2007 and is based in Tel Aviv, Israel.
PainReform Ltd.
| Country | Israel |
| Founded | 2007 |
| IPO Date | Sep 1, 2020 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 7 |
| CEO | Ehud Geller |
Contact Details
Address: 65 Yigal Alon St. Tel Aviv, 6744316 Israel | |
| Phone | 972 3 7177050 |
| Website | painreform.com |
Stock Details
| Ticker Symbol | PRFX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $8.00 |
| CIK Code | 0001801834 |
| CUSIP Number | M77798102 |
| ISIN Number | IL0011651580 |
| SIC Code | 2834 |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 27, 2025 | 6-K | Report of foreign issuer |
| Feb 26, 2025 | 6-K | Report of foreign issuer |
| Feb 18, 2025 | 6-K | Report of foreign issuer |
| Jan 2, 2025 | 424B5 | Filing |
| Jan 2, 2025 | 6-K | Report of foreign issuer |
| Dec 27, 2024 | 6-K | Report of foreign issuer |
| Dec 12, 2024 | EFFECT | Notice of Effectiveness |
| Dec 12, 2024 | 424B3 | Prospectus |
| Dec 11, 2024 | UPLOAD | Filing |
| Dec 6, 2024 | F-3 | Filing |